Skip to content

Efficacy and safety of retinal rejuvenation using Ellex 2RT laser in age-related maculopathy

Efficacy and safety of retinal rejuvenation using Ellex 2RT laser in age-related maculopathy (RETILASE trial)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN87850962
Enrollment
80
Registered
2012-02-20
Start date
2011-12-15
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Eye

Interventions

The patients will be randomised to either have a one off laser treatment to the macula of one eye (2RT, nano second laser technology 400um spot size at least 25 spots) and the patients in the control

Sponsors

King's College Hospital NHS Foundation Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients of either sex aged 55 years or over 2. Diagnosis of age-related maculopathy that meet the criteria of large drusen (=125 µ) in at least 1 eye 3. Best corrected visual acuity in the study eye between 50 to 90 ETDRS letters at baseline visit 4. Media clarity, pupillary dilation, and subject cooperation sufficient for adequate fundus photographs 5. No previous macular laser therapy to study eye 6. Written informed consent and willingness and ability to be followed up for 24 months Target Gender: Male & Female; Upper Age Limit 90 years; Lower Age Limit 55 years

Exclusion criteria

Exclusion criteria: 1. Drusenoid PED, Choroidal neovascularisation and geographic atrophy in the study eye 2. Macular ischaemia (FAZ > 1000µm in diameter or moderate perifoveal capillary loss in fluorescein angiogram) or diabetic retinopathy 3. Macular oedema of any cause such as wet AMD, diabetic macular oedema, pseudophakic macular oedema or taut posterior hyaloid 4. Co-existent ocular disease that in the investigator?s discretion would lead to decrease visual acuity by 3 lines or more by end of 12 months 5. History of thermal lasers or treatment with intravitreal antiVEGF agents or steroids for any retinal conditions 6. Participation in an investigational trial within 30 days of randomisation that involved treatment with any drug including those that has not received regulatory approval at the time of study entry 7. Anticipated major ocular surgery (including cataract extraction) for the period of the trial 8. Amblyopia in study eye 9. Known allergy to fluorescein dye or to any component of the study drug 10. Pregnancy at baseline and the patient will be withdrawn from the study if she becomes pregnant during the course of the study

Design outcomes

Primary

MeasureTime frame
Visual acuity; Timepoint(s): 1 year

Secondary

MeasureTime frame
Not provided at time of registration

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026